Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Decrease of Serum TARC Levels As Predictive Biomarkers of Response to Targeted Therapy with Kinase Inhibitors in Refractory/Relapsed Hodgkin Lymphoma Patients

Anna Guidetti, MD, Simonetta Viviani, MD, Anna Dodero, MD, Lucia Farina, MD, Domenico Russo, MD PhD, Pietro Bulian, Massimo Di Nicola, MD, Arabella Mazzocchi, MD, Fernando Ravagnani, MD, Paolo Corradini, MD, Alessandro Massimo Gianni, MD, Carmelo Carlo-Stella, MD

Blood (2014) 124 (21): 4459.

https://doi.org/10.1182/blood.V124.21.4459.4459

Published: 2014

Journal Articles

High Cure Rates of the Short-Term GITIL Chemotherapy Programme for Adult Patients with Burkitt Lymphoma

Jacopo Mariotti, MD, Anna Guidetti, MD, Michele Magni, MD, Paola Matteucci, MD, Liliana Devizzi, MD, Andrés J.M. Ferreri, Paolo Corradini, MD, Anna Dodero, MD, Amalia De Renzo, Alessandro Massimo Gianni, MD, Massimo Di Nicola, MD

Blood (2014) 124 (21): 1734.

https://doi.org/10.1182/blood.V124.21.1734.1734

Published: 2014

Journal Articles

HSP105 Inhibition Counteracts Key Oncogenic Pathways and Hampers the Growth of Human Aggressive B-Cell Non-Hodgkin Lymphoma

Roberta Zappasodi, PhD, Alessandra Cavanè, Monica Tortoreto, Cristina Tringali, Giusi Ruggiero, Lorenzo Castagnoli, Bruno Venerando, Nadia Zaffaroni, Serenella M Pupa, Alessandro Massimo Gianni, MD, Massimo Di Nicola, MD

Blood (2012) 120 (21): 1562.

https://doi.org/10.1182/blood.V120.21.1562.1562

Published: 2012

Journal Articles

Chemoimmunotherapy with R-CHOP or High Dose Sequential Therapy with Autologous Stem Cell Transplantation (R-HDS) for High Risk Diffuse Large B-Cell Lymphomas Patients: Results of the Randomized R-HDS0305 Trial by Gruppo Italiano Terapie Innovative Nei Linfomi (GITIL)

Blood (2012) 120 (21): 746.

https://doi.org/10.1182/blood.V120.21.746.746

Published: 2012

Journal Articles

TARC Is Useful as Additional Prognostic Factor for Hodgkin's Lymphoma Outcome.

Simonetta Viviani, MD, Arabella Mazzocchi, Valeria Bonfante, Rosalba Miceli, MD, Davide Dalu, MD, Marina Galbiati, Fernando Ravagnani, Luigi Mariani, Alessandro Massimo Gianni

Blood (2009) 114 (22): 1557.

https://doi.org/10.1182/blood.V114.22.1557.1557

Published: 2009

Journal Articles

Reduced-Intensity Conditioning Followed by Allogeneic Stem Cell Transplantation (allo-SCT) Is an Effective Salvage Treatment for Peripheral T-Cell Non-Hodgkin’s Lymphoma (PTCL).

Paolo Corradini, MD, Anna Dodero, MD, Marco Bregni, MD, Francesco Zallio, MD, Lucia Farina, MD, Alessandro Rambaldi, MD, Francesca Patriarca, MD, Attilio Olivieri, MD, Francesca Bonifazi, MD, Alessandro Massimo Gianni, MD, Corrado Tarella, MD

Blood (2005) 106 (11): 1128.

https://doi.org/10.1182/blood.V106.11.1128.1128

Published: 2005

Journal Articles

Reduced-Intensity Conditioning (RIC) Followed by Allogeneic Stem Cell Transplantation (SCT) for Relapsed Lymphomas: Impact of Pre-Transplantation Factors on Long-Term Outcome.

Paolo Corradini, MD, Anna Dodero, MD, Marco Bregni, MD, Fabio Ciceri, MD, Attilio Olivieri, MD, Lucia Farina, MD, Pinuccia Valagussa, MD, Rosanna Scime’, MD, Anna Locasciulli, MD, Francesca Patriarca, MD, Alessandro Massimo Gianni, MD, Corrado Tarella, MD

Blood (2005) 106 (11): 1129.

https://doi.org/10.1182/blood.V106.11.1129.1129

Published: 2005

Journal Articles

Reduced-Intensity Conditioning (RIC) Followed by Allogeneic Transplantation in Relapsed Lymphomas: Evidence for Graft-Versus-Lymphoma Effect in Low and High Grade Histologies, but Not in Hodgkin Disease.

Paolo Corradini, MD, Anna Dodero, MD, Marco Bregni, MD, Attilio Olivieri, MD, Lucia Farina, MD, Elena Rizzo, MD, Raffaella Milani, MD, Rosanna Scime, MD, Alessandro Rambaldi, MD, Francesca Bonifazi, MD, Francesca Patriarca, MD, Anna Locasciulli, MD, Andrea Bacigalupo, MD, Alessandro Massimo Gianni, MD, Corrado Tarella, MD

Blood (2004) 104 (11): 808.

https://doi.org/10.1182/blood.V104.11.808.808

Published: 2004

Journal Articles

Long-Term Follow-Up of High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Peripheral T-Cell Lymphomas at Diagnosis.

Sergio Cortelazzo, MD, Corrado Tarella, MD, Anna Dodero, MD, Alessandro Massimo Gianni, MD, Zallio Francesco, MD, Manuela Zanni, MD, Alessandro Rambaldi, MD, Tiziano Barbui, MD, Paolo Corradini, MD

Blood (2004) 104 (11): 909.

https://doi.org/10.1182/blood.V104.11.909.909

Published: 2004

NARROW

Decrease of Serum TARC Levels As Predictive Biomarkers of Response to Targeted Therapy with Kinase Inhibitors in Refractory/Relapsed Hodgkin Lymphoma Patients

High Cure Rates of the Short-Term GITIL Chemotherapy Programme for Adult Patients with Burkitt Lymphoma

HSP105 Inhibition Counteracts Key Oncogenic Pathways and Hampers the Growth of Human Aggressive B-Cell Non-Hodgkin Lymphoma

Chemoimmunotherapy with R-CHOP or High Dose Sequential Therapy with Autologous Stem Cell Transplantation (R-HDS) for High Risk Diffuse Large B-Cell Lymphomas Patients: Results of the Randomized R-HDS0305 Trial by Gruppo Italiano Terapie Innovative Nei Linfomi (GITIL)

TARC Is Useful as Additional Prognostic Factor for Hodgkin's Lymphoma Outcome.

Reduced-Intensity Conditioning Followed by Allogeneic Stem Cell Transplantation (allo-SCT) Is an Effective Salvage Treatment for Peripheral T-Cell Non-Hodgkin’s Lymphoma (PTCL).

Reduced-Intensity Conditioning (RIC) Followed by Allogeneic Stem Cell Transplantation (SCT) for Relapsed Lymphomas: Impact of Pre-Transplantation Factors on Long-Term Outcome.

Reduced-Intensity Conditioning (RIC) Followed by Allogeneic Transplantation in Relapsed Lymphomas: Evidence for Graft-Versus-Lymphoma Effect in Low and High Grade Histologies, but Not in Hodgkin Disease.

Long-Term Follow-Up of High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Peripheral T-Cell Lymphomas at Diagnosis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only